G1 arrest via thymidine treatment in mESCs shows reproducibility while maintaining pluripotency.

(A). Loadings of the first two principal components from principal component analysis of the three RNA-seq replicates after 20-h G1 arrest via thymidine treatment, along with asynchronous controls. Thymidine-treated samples separate from asynchronous controls while clustering together amongst themselves. (B). Log₂ normalized RNA counts of key pluripotency and differentiation markers from the RNA-seq replicates shown in (A). Expression of the pluripotency markers Nanog and Oct4 are high in both thymidine-treated and asynchronous samples, while differentiation markers remain low in both conditions. Data underlying this figure can be found in S8 Data.

(PDF)